Skip to main content
The Prof G Pod

No Mercy / No Malice: The Weight

15 min episode · 2 min read
·

Episode

15 min

Read time

2 min

Topics

Startups, Leadership, Sales & Revenue

AI-Generated Summary

Key Takeaways

  • GLP-1 Market Expansion: Eli Lilly's stock rose 418% since 2021 GLP-1 approval, reflecting the category's explosive growth. New drugs like retatrutide show 29% body weight loss at 12mg doses, while the FDA-approved daily pill Orforglipron offers an alternative for the 66 million Americans who avoid needles.
  • Access as the Core Barrier: A Cleveland Clinic study found 47% of GLP-1 discontinuations stem from cost — insurance denial, expired coupons, or unaffordable out-of-pocket expenses. Only 14% quit due to side effects. Medicare Part D coverage beginning July 1 caps costs at $50 monthly, but private insurers are scaling back.
  • Consumer Behavior Shift: GLP-1 users consume 21% fewer calories and spend nearly one-third less on groceries. Fast food chains including Jack in the Box and Wendy's are closing hundreds of locations amid 500-plus franchisee bankruptcies, while Victoria's Secret surged 47% on revenue growth tied to shifting body size trends.
  • Pharmaceutical Economics Reversal: Eli Lilly CEO David Ricks confirmed GLP-1 pricing behaves unlike traditional drugs — demand rises as prices fall, making this a rare case of elastic pharmaceutical pricing. However, the long-term dependency model mirrors a subscription business with monthly costs between $149 and $499.

What It Covers

Scott Galloway argues GLP-1 drugs represent the most transformative technology in the US economy, with obesity rates declining for the first time in decades, while access inequality and insurance rollbacks threaten to limit their societal impact.

Key Questions Answered

  • GLP-1 Market Expansion: Eli Lilly's stock rose 418% since 2021 GLP-1 approval, reflecting the category's explosive growth. New drugs like retatrutide show 29% body weight loss at 12mg doses, while the FDA-approved daily pill Orforglipron offers an alternative for the 66 million Americans who avoid needles.
  • Access as the Core Barrier: A Cleveland Clinic study found 47% of GLP-1 discontinuations stem from cost — insurance denial, expired coupons, or unaffordable out-of-pocket expenses. Only 14% quit due to side effects. Medicare Part D coverage beginning July 1 caps costs at $50 monthly, but private insurers are scaling back.
  • Consumer Behavior Shift: GLP-1 users consume 21% fewer calories and spend nearly one-third less on groceries. Fast food chains including Jack in the Box and Wendy's are closing hundreds of locations amid 500-plus franchisee bankruptcies, while Victoria's Secret surged 47% on revenue growth tied to shifting body size trends.
  • Pharmaceutical Economics Reversal: Eli Lilly CEO David Ricks confirmed GLP-1 pricing behaves unlike traditional drugs — demand rises as prices fall, making this a rare case of elastic pharmaceutical pricing. However, the long-term dependency model mirrors a subscription business with monthly costs between $149 and $499.

Notable Moment

Galloway notes that US obesity rates, after tripling over 60 years and peaking at 40%, have begun declining — the first reversal in decades — directly attributable to GLP-1 adoption, with one in eight American adults now prescribed these drugs.

Know someone who'd find this useful?

Episode Transcript

Support for the show comes from Odoo. Running a business takes everything you've got. And a lot of the tools out there that are supposed to make your life easier just aren't great talking to each other. And that means you end up having to toggle between a dozen different apps and services just to keep the lights on. Enough of that. Now there's Odoo, the all in one fully integrated platform that might actually help you get it all done. Thousands of businesses have made the switch, so why not you? Try Odoo for free at odoo.com. That's odoo.com. It's true that some things change as we get older. But if you're a woman over 40 and you're dealing with insomnia, brain fog, moodiness, and weight gain, you don't have to accept it as just another part of aging. And with Mitty Health, you can get help and stop pushing through it alone. The experts at Mitty understand that all these symptoms can be connected to the hormonal changes that happen around menopause. And MiddI can help you feel more like yourself again. Many healthcare providers aren't trained to treat or even recognize menopause symptoms. MiddI clinicians are menopause experts. They're dedicated to providing safe, effective, FDA approved solutions for dozens of hormonal symptoms, not just hot flashes. Most importantly, they're covered by insurance. Ninety one percent of many patients get relief from symptoms within just two months. You deserve to feel great. Book your virtual visit today at joinmidi.com. That's join,midi,.com. Support for this show comes from Odoo. Running a business is hard enough, so why make it harder with a dozen different apps that don't talk to each other? Introducing Odoo. It's the only business software you'll ever need. It's an all in one fully integrated platform that makes your work easier. CRM, accounting, inventory, e commerce and more. And the best part? Odoo replaces multiple expensive platforms for a fraction of the cost. That's why over thousands of businesses have made the switch. So why not you? Try Odoo for free at odoo.com. That's odoo.com. I'm Scott Galloway, and this is No Mercy, No Malice. The most transformative technology with the greatest asymmetric upside isn't ChatGPT five, but GLP ones. The wait, as read by George Hahn. God. I'm sick of talking about SpaceX. More impressive than the Falcon Heavy rocket, and it is impressive, is Elon Inc's ability to manufacture scarcity. Getting the Nasdaq to waive requirements applied to every company until now so he can force index funds to purchase shares aims a demand canon of $75,000,000,000 at a business with a small float. The result is a price that in no way reflects the underlying value. But I digress. This isn't an investment, but a trade. So where to invest? The technology with the greater asymmetric upside as well as the clearest path to transforming the economy and the well-being of more than 200,000,000 Americans isn't Falcon nine boosters or GPT five, but …

Get the full transcript (2,166 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Prof G Pod transcripts →

You just read a 3-minute summary of a 12-minute episode.

Get The Prof G Pod summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

Books, tools, and gear mentioned in this episode

SignalCast may earn commission on purchases via these links. As an Amazon Associate, SignalCast earns from qualifying purchases.

Products

  • the FDA-approved daily pill Orforglipron offers an alternative for the 66 million Americans who avoid needles.
  • New drugs like retatrutide show 29% body weight loss at 12mg doses

company

  • Eli Lilly's stock rose 418% since 2021 GLP-1 approval, reflecting the category's explosive growth.
  • A Cleveland Clinic study found 47% of GLP-1 discontinuations stem from cost
  • Fast food chains including Jack in the Box and Wendy's are closing hundreds of locations
  • Fast food chains including Jack in the Box and Wendy's are closing hundreds of locations
  • Victoria's Secret surged 47% on revenue growth tied to shifting body size trends.

More from The Prof G Pod

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Business Podcasts (2026) — ranked and reviewed with AI summaries.

Read this week's Startups & Product Podcast Insights — cross-podcast analysis updated weekly.

You're clearly into The Prof G Pod.

Every Monday, we deliver AI summaries of the latest episodes from The Prof G Pod and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime